A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy

Exclusion Criteria

• •Active or untreated central nervous system (CNS) metastases
• •Spinal cord compression not definitively treated or not clinically stable
• •Leptomeningeal disease
• •Uncontrolled pleural or pericardial effusions or ascites requiring recurrent drainage
• •Uncontrolled tumor-related pain
• •Uncontrolled hypercalcemia
• •Malignancies other than NSCLC within 5 years prior to randomization, except for those curatively treated with negligible risk of metastasis or death
• •Pregnant or lactating women
• •Significant cardiovascular, pulmonary, or autoimmune disease
• •Severe infection or major surgery within 4 weeks, or antibiotic treatment within 2 weeks prior to randomization
• •Prior treatment with or hypersensitivity to study drug(s) or related compounds
• •Inability to discontinue strong cytochrome P450 (CYP) 3A4 inhibitors
• •Prior allogeneic bone marrow or solid organ transplant
• •Known PD-L1-negative expression status
• •Positive human immunodeficiency virus (HIV) or active hepatitis B or C
• •Receipt of a live attenuated vaccine within 4 weeks prior to randomization
• •Treatment with systemic immunomodulators within 4 weeks or five half-lives (whichever is shorter) prior to randomization
• •Treatment with systemic corticosteroids within 2 weeks prior to randomization